What is Imunon?
Imunon operates at the forefront of the biotechnology sector, specializing in the development of innovative DNA-based immunotherapies and vaccines. By utilizing proprietary non-viral nucleic acid delivery platforms, the company aims to modulate the body's immune system to combat challenging cancers and infectious diseases. This approach emphasizes the creation of durable therapeutic responses by harnessing natural biological mechanisms. With integrated research, development, and manufacturing capabilities, Imunon is uniquely positioned to transition its novel immunology-driven medicines from the laboratory to clinical application, targeting significant unmet medical needs across a diverse range of serious health conditions.
How much funding has Imunon raised?
Imunon has raised a total of $10M across 1 funding round:
Stock/Share Issuance
$10M
Stock/Share Issuance (2026): $10M, investors not publicly disclosed
Key Investors in Imunon
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Imunon?
The recent infusion of capital provides Imunon with the necessary resources to scale its clinical operations and refine its manufacturing processes. As the company moves forward, the strategic focus will likely center on advancing its lead candidates through rigorous clinical trials and expanding its intellectual property portfolio. By leveraging its non-viral delivery technology, Imunon aims to solidify its market position as a leader in the next generation of immunotherapy. Investors and stakeholders will be closely monitoring the company's progress in achieving key clinical milestones, which are essential for validating the efficacy of its platform and securing long-term commercial viability in the competitive biotech landscape.
See full Imunon company page
